A Cytomegalovirus vaccine is a vaccine to prevent cytomegalovirus (CMV) infection or to prevent it re-activation in those who are already infected. As of 2014 no such a vaccine exists, although a number of vaccine candidates are under investigation. They include recombinant protein, live attenuated, DNA and other vaccines.
As a member of the TORCH complex, cytomegalovirus can cause congenital infection, which can lead to neurological problems, vision and hearing loss. Infection/re-activation of CMV in immuno-compromised persons, including organ transplantation recipients, causes significant mortality and morbidity. Because of all these, there has been considerable effort made towards the development of a vaccine, with particular emphasis on protection of pregnant women. Since vaccination of the immunocompromised persons introduces additional challenges, members of this population are less likely to be candidates for such a vaccine.
Recombinant gB subunit vaccine
A phase 2 study of a recombinant gB subunit CMV-vaccine published in 2009 indicated an efficacy of 50% in seronegative women of childbearing age—thus the protection provided was limited and a number of subjects contracted CMV infection despite the vaccination. In one case congenital CMV was encountered.
Another phase 2 study of the same vaccine was done in patients awaiting kidney transplantation. The vaccine significantly boosted the antibody levels and reduced the duration of post-transplantation viremia.
- Dasari, V.; Smith, C.; Khanna, R. (2013). "Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases". Expert Review of Vaccines 12 (6): 661. doi:10.1586/ERV.13.46. PMID 23750795.
- Zhong J, Rist M, Cooper L, Smith C, Khanna R (2008). "Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus". PLoS ONE 3 (9): e3256. doi:10.1371/journal.pone.0003256. PMC 2533118. PMID 18806877.
- Schleiss MR (March 2008). "Comparison of vaccine strategies against congenital CMV infection in the guinea pig model". J. Clin. Virol. 41 (3): 224–30. doi:10.1016/j.jcv.2007.10.008. PMID 18060834.
- Schleiss MR, Heineman TC (June 2005). "Progress toward an elusive goal: current status of cytomegalovirus vaccines". Expert Rev Vaccines 4 (3): 381–406. doi:10.1586/147605188.8.131.521. PMID 16026251.
- Khanna R, Diamond DJ (January 2006). "Human cytomegalovirus vaccine: time to look for alternative options". Trends Mol Med 12 (1): 26–33. doi:10.1016/j.molmed.2005.11.006. PMID 16337831.
- Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R (July 2004). "Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee". Clin. Infect. Dis. 39 (2): 233–9. doi:10.1086/421999. PMID 15307033.
- Pass RF, Zhang C, Evans A et al. (2009). "Vaccine prevention of maternal cytomegalovirus infection". N Engl J Med 360 (12): 1191–9. doi:10.1056/NEJMoa0804749. PMC 2753425. PMID 19297572.